Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
96 Cards in this Set
- Front
- Back
trxt of acute gout targets
|
inflammation
|
|
trxt of chronic gout targets
|
both inflamm processes and prod/elim of uric acid
|
|
what tissue type does inflamm primarily occur
|
vascularized CT
|
|
enzymes at the head of the enzymatic path for PG
|
COX
|
|
how fast is the onset of DMARDs
|
slow (weeks to months)
|
|
what differentiates NSAIDs from steroids
|
NSAIDs inhibit COX, steroids mediate anti-inflamm effects via activation of glucocorticoid receptors
|
|
rare syndrome of rapid liver degen and encephalitis in children treated w aspirin during a viral inf
|
reye syndrome
|
|
cytokine that plays central role in inflamm
|
TNF-alpha
|
|
drug that increases renal excretion of uric acid
|
uricosuric agent
|
|
key enzyme in purine metab pathway that ends w prod of uric acid
|
xanthine oxidase
|
|
prototype of salicylates
|
aspirin
|
|
older nonselective NSAIDs
|
ibuprofen, indomethacin
|
|
effectiveness of ibuprofen, naproxen, indomethacin and ketorolac
|
ibuprofen and naproxen = moderate; indomethacin has greater anti-inflamm, ketorolac has greater analgesic
|
|
celecoxib
|
COX2 inhibitor
|
|
COX2 decrease ____ but increase ____ side effects
|
GI distress, CV thrombotic events
|
|
COX converts
|
arachidonic acid into the endoperoxide precursors of PG
|
|
where is COX 1 and 2 expressed
|
COX 1 = noninflamm cells, COX 2 = activated lymphocytes, PMNs and other inflamm cells
|
|
aspririn and nonselective NSAIDs decrease synthesis of
|
PG and thromboxane
|
|
COX 2 inhibitors have less effect on what PG
|
those involved in homeostatic fxn esp in GI tract
|
|
diff in MOA between aspirin and other NSAIDs
|
aspirin acetylates and thereby irrev inhibits COX
|
|
irrev action of aspirin results in longer duration of
|
antiplatelet effect
|
|
antipyretic action of NSAIDs by inhibiting PG synth in
|
CNS stimulated by pyrogens
|
|
analgesic MOA of NSAIDs
|
decreased PG prod = decreased activ of periph pain sensors
|
|
COX inhibitors most importantly do what to GI and renal fxn
|
decr PG mediated cytoprotection in GI tract and autoregul of kidney fxn
|
|
3 therapeutic dosages of aspirin
|
low (<300) = antiplatelet
intermed (300-2400)=antipyretic and analgesic high (2400-4000)=anti-inflamm |
|
what is aspirin hydrolyzed to in blood and tissues
|
acetate and salicylic acid
|
|
salicylate is ____ inhibitor of COX
|
reversible
|
|
at low doses, elim of salicylate is what order
|
first
|
|
at high doses, elim of salicylate is what order
|
zero
|
|
site of excretion of NSAIDs
|
kidney
|
|
site of excretion of acetaminophen
|
liver
|
|
half life of ibuprofen
|
2hrs
|
|
naproxen and piroxican are notable because
|
have longer half lives
|
|
ketorolac is notable as drug used mainly as
|
systemic analgesic
|
|
only NSAID availabile in parenteral form
|
ketorolac
|
|
what reduce polyp formation in pts w primary familial adenomatous polyposis
|
nonselective NSAIDs
|
|
long term use of NSAIDS reduces risk of
|
colon cancer
|
|
most common adverse effect from therapeutic anti-inflamm doses of aspirin
|
gastric upset
|
|
chronic aspirin use can cause
|
gastric ulcers, upper GI bleeding, renal effects
|
|
aspriin hypersensitivity pts experience ___ due to increased leukotriene synth
|
asthma
|
|
SE at high doses of aspirin
|
tinnitus, vertigo, hyperventil, resp alkalosis
|
|
SE at very high doses of aspirin
|
metab acidosis, dehydration, hyperthermia, collapse, coma, death
|
|
NSAIDS should not be used in pts w exisiting
|
renal disease
|
|
use of ____is restricted to 72h due to risk of GI and renal damage
|
parenteral ketorolac
|
|
indomethacin can cause
|
serious hematologic rxns
|
|
celecoxib, rofecoxib, valdecoxib have reduced risk of
|
GI effects
|
|
rofecoxib and valdecoxib have increased risk of
|
MI and stroke
|
|
why is there an incr risk of thrombosis w COX 2 inhibitors
|
they have greater inhib effects on endothelial PG (PGI2) than on platelet TXA2 formation
|
|
prostacyclin promotes
|
vasodil and inhibits platelet aggreg
|
|
TXA2 promotes
|
vasoconstrict and platelet aggreg
|
|
only OTC NSAID avail in US
|
acetaminophen
|
|
toxic prodrug metabolized to acetaminophen
|
phenacetin
|
|
why does acetaminophen lack anti-inflamm effects
|
weak COX1, COX2 inhibitor
|
|
what agent is acetaminophen
|
antipyretic, analgesic
|
|
acetaminophen is effective for same indications as
|
intermed dose aspiriin
|
|
half life of acetaminophen
|
2-3hr
|
|
when is acetaminophen a dangerous hepatotoxin
|
overdosed in pts w severe liver impairment
|
|
mech of toxicity of acetaminophen
|
oxid to cytotoxic intermed by phase I cyt P450 enzymes if substrates for phase II conj rxns (acetate and glucuronide) are lacking
|
|
acetaminophen overdose antidote
|
acetylcysteine
|
|
who is at incr risk for acetaminophen induced hepatotoxicity
|
those who drink 3+ alcoholic drinks per day
|
|
considered anti-inflamm drugs w intermed rate of action
|
corticosteroids
|
|
MOA of methotrexate
|
reducing # of immune cells avail to maintain inflamm response
|
|
sulfasalazine, hydroxychloroquine, cyclosporine all interfere with activity of
|
T lymphocytes
|
|
what drug interferes w B lymphocytes
|
rituximab
|
|
what drugs inhibit TNF-alpha
|
infliximab, adalimumab, etanercept
|
|
anti TNF-alpha drugs are given via what route
|
injection
|
|
3 trxt strategies for gout and drugs that address each
|
decr inflamm (colchicine, NSAIDs, glucocorticoids), incr uric acid excretion (probenecid), decr uric acid prod (allopurino, febuxostat)
|
|
purines-->uric acid via
|
xanthine oxidase
|
|
NSAID that is effective at inhibiting inflamm of acute gouty arthritis
|
indomethacin
|
|
selective inhibitor of microtubule assembly that reduces leukocyte migration and phagocytosis
|
colchicine
|
|
reduces prod of LTB4 and free radical formation
|
colchicine
|
|
general mitotic poison
|
colchicine
|
|
preferred trxt for acute gouty arthritis
|
NSAID or glucocorticoid
|
|
lower doses of ___ used to prevent attacks of gout in pts w hx of multiple acute attacks
|
colchicine
|
|
drug used in management of familial mediterranean fever
|
colchicine
|
|
colchicine can be given by what routes
|
oral, parenteral
|
|
can cause bone marrow depression
|
indomethacin
|
|
can cause behavioral changes and impaired glucose control
|
short courses of glucocorticoids
|
|
colchicine can severly damage
|
liver and kidney
|
|
high doses of colchicine can cause
|
severe GI disturbance esp diarrhea
|
|
where is 90% of uric acid reabsorbed
|
PCT
|
|
weak acids that compete w uric acid for reabsorption in PCT
|
probenecid, sulfinpyrazone
|
|
when can serum uric acid conc be elevated by drug rather than reduced
|
low doses of probenecid and sulfinpyrazone when they compete w uric acid for secretion...or with aspirin
|
|
what do uricosuric drugs inhibit
|
secretion of other weak acids and reabsorp of uric acid
|
|
what drugs are of no value in acute episodes
|
uricosuric drugs
|
|
how can acute gout attack during early phase of action of uricosuric drugs be avoided
|
simult admin of colchicine or indothemacin
|
|
uricosuric share allergenicity w
|
sulfonamid drugs
|
|
enzyme that converts hypoxanthine to xanthine and xanthine to uric acid
|
xanthine oxidase
|
|
converts allopurinol to oxypurinol (alloxanthine)
|
xanthine oxidase
|
|
irrev suicide inhibitor of xanthine oxidase
|
alloxanthine
|
|
nonpurine inhibitor of xanthine oxidase
|
febuxostat
|
|
what is more effective than allopurinol in lowering serum uric acid
|
febuxostat
|
|
xanthine oxidase inhib and uricosuric drugs are withheld for ___ after acute attack of gouty arthritis
|
1-2wks
|
|
adjunct to cancer chemotherapy to slow formation of uric acid from purines released by death of large numbers of neoplastic cells
|
allopurinol
|
|
SE of allopurinol
|
GI upset, rash, periph neuritis, vasculitis, BM dysfxn incl aplastic anemia
|
|
SE of febuxostat
|
liver fxn abnorm, h/a, GI upset
|